Immunodiagnostic Systems Share Discussion Threads

[wigwammer] 26/10/2020 09:44

Did they post this after hours on a Friday so some people wouldn't see it? Twonks.

[weemonkey] 26/10/2020 09:01

hugely disappointing update... clearly no take up on this covid test either

[undervaluedassets] 09/10/2020 08:45

Now that is what I call a piece of news

toe in ...

[allstars001] 21/9/2020 13:02

Surprising to see nil volume today?Nobody settling for the profits?

[mcrudden] 27/8/2020 07:59

Tumble weed in here today

[mcrudden] 18/8/2020 15:32

pinged off the lows in the chart and closed the gap. Taken more today to average down, I'll review in 1 month but I reckon I'll be selling these at least twice the price from here.

[faz] 13/8/2020 18:53

You cannot buy and sell in any quantity. What investor buys shares he/she cannot sell? Today I would bet many holders have used the opportunity to get out while they can. The company would be better off going private if it won't do anything to sponsor liquidity in its shares.

[colin12345678] 13/8/2020 16:08

Josh that bad ??? its the fastest test out there

[josh 32] 13/8/2020 15:50

So after that rns the share price is worth 4 percent less than yesterday before that rns I didn't think the news was that bad

[mcrudden] 13/8/2020 13:06

Very valuable to healthcare professionals indeed. Most missed that rns but worth having a good read through and google some recent studies done in the U.K.

[wigwammer] 13/8/2020 07:32

"The ability to test IgG and IgM antibodies simultaneously from the same sample tube, on the same automated analyzer, will provide a valuable diagnostic complement to RT-PCR tests used to detect the COVID-19 virus." ... older tech will still have a role to play :)

[hedgehog 100] 23/7/2020 15:40

23/07/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC AGM Statement

" ... COVID-19 Testing Range

As announced on 30 June, we released our automated SARS-Cov2-IgG test in countries that accept the CE mark. Interest from our direct and distribution customers has been strong and initial feedback from their validation

processes positive. The first sales of this test were made during July. We are hoping to launch a complimentary SARS-Cov2-IgM automated test in the coming months. Furthermore, we are also providing contract manufacturing services to a developer of an ELISA based test, and produced the first prototype batches in June and July.
These products have great potential, though it is too early to estimate the revenue levels which they will generate. We are confident IDS have enough capacity for analyser instruments and assay manufacturing to meet likely demand. ..."

[hedgehog 100] 01/7/2020 14:55

"Technogenetics is part of the KHB Group and engages in complex and ambitious challenges with the aim of offering the market increasingly efficient and advanced diagnostic solutions. Listed on the Shenzhen Stock Exchange and headquartered in Shanghai, KHB, Shanghai Kehua Bio-engineering Co. Ltd was founded in 1981 and is a leading manufacturer of IVD reagents and instruments in China. By focusing its activities on R&D and relying on the contribution of many excellent professionals, over the years KHB has achieved a position as a global standard setter for scientific research and obtained many important registrations for its products: SFDA for over 100 products and CE marking for over 60. Supported by over 700 distributors in China and many more abroad, KHB is a leading Chinese company with a significant and growing international footprint. In particular, KHB is one of the global suppliers of WHO, UNICEF, PEPFAR and the Clinton HIV/AIDS Initiative."



"About Shanghai Kehua Bio-Engineering Co., Ltd.

Shanghai Kehua Bio-Engineering Co., Ltd. (hereinafter referred to as KHB, Stock code: 002022.SZ) is a Chinese IVD company that boasts a full line of medical diagnostic products. Over the three decades since its foundation in 1981, KHB has developed into a hi-tech company that integrates R&D, manufacturing and marketing business operation covering the whole industrial chain of IVD sector. In 2004, it was listed in the SME Board of Shenzhen Stock Exchange (SZSE).

Being a national certified Chinese hi-tech enterprise headquartered in Shanghai, KHB has set up R&D centers and production bases in a number of countries and regions including Italy, Shenzhen, Xi’an, and Suzhou. The company has 1,800+ employees, 200+ product registration certificates, and more than 70 CE certified reagent and instrument products, and has established long-term partnership with more than a thousand of domestic agents and 18 international agents. KHB branded products have been exported to 40 foreign countries and regions, and AIDS diagnostic reagents in-housed developed by KHB that passed WHO PQ have been listed in the purchase catalogs in many countries.

KHB has professional technology R&D and production teams which, backed by the company's biotechnology innovation center and postdoctoral research workstation, have built two technology platforms for the R&D of clinical IVD reagents and full automatic analyzers and the innovative implementation of seriation and integration of reagents and instruments. KHB is dedicated to the provision of high quality products and service to the public in order to safeguard the happiness of millions of families by virtue of its focused R&D innovation efforts in the core technical areas of immunodiagnosis, biochemical diagnosis, and molecular diagnosis in support of the management of hepatopathy, maternal & child health, and nephropathy.

Inspired by its corporate vision -"Care for life , Dedicate to excellence" - KHB is embracing the core values of "Innovative, Accountable, Pragmatic, Collaborative, upholding" its "product-centered and market-oriented" business philosophy, and adhering to its audacity to innovate in order to continually achieve new leap forward and new breakthrough in company development in support of its ambition to be a leading professional and global Chinese IVD listed company. Originated in Shanghai · Rooted in China · Embracing the World."

[hedgehog 100] 01/7/2020 14:22

Well done and thanks to IDH's management for launching this COVID-19 antibody test bang on schedule, and for keeping the market so well updated.

They look to have played an absolute blinder here in launching this 'platinum standard test' that could be a 'licence to print money'.

And at just 270p IDH still isn't at much of a premium to the 240p+ that it was at for most of the spring, despite this game-changing development from the company.

Though I would expect that to change over time.


30/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Launch of assay to detect SARS-CoV-2 antibodies

"Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 12 June, our fully automated SARS-CoV-2 IgG antibody test ("the Test") will be available for sale from today.

The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centers and governmental bodies to ensure a roll-out according to national guidelines.

Jaap Stuut, CEO of IDS commented

"We are pleased to announce the release to the market of our automated SARS -CoV-2 antibody test, running on the IDS-iSYS analyser. IDS will now seek to commercialise this test via our direct sales force in Europe, and through our extensive distribution network elsewhere, and we look forward to joining the efforts to minimise the impact of the COVID-19 virus."

About the Test

The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the installed base of over 600 automated IDS-iSYS analysers. The Test:

-- Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response;
-- Is a quantitative test which determines antibody concentration (titer);
-- Is highly accurate with a sensitivity of 100% and a specificity of 99.4%;
-- Provides Test results available within 25 minutes.

Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay, thus it can determine the antibody concentration in patient serum. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood.

All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput."

[dozey3] 30/6/2020 09:24

Today’s rns says the COVID antibody test is now up and running. It is highly accurate, quantitative, and delivers the result in 25 minutes as we already know. Hopefully the ‘better mousetrap’ that will bring stellar results for the community and shareholders,

[paleales] 29/6/2020 05:27

tinyurl.com/yckf5fch
#BOOOOOOOOOOOOOMM #N4P
@n4pharma

- £186 million government funding from UK Research and Innovation’ - Evotec are involved, i think Nigel has played a blinder here by getting Evo to do the proofing work

[hedgehog 100] 27/6/2020 16:58

2toptrader,

Stocks being pumped to overvaluations will come down, whereas better value stocks will move up. -

Benjamin Graham:
“In the short run, the market is a voting machine but in the long run, it is a weighing machine.”


Warren Buffett:
"I would rather be certain of a good result than hopeful of a great one."


At just 240p IDH is looking massively oversold, and nicely poised for a big imminent rebound.

[2toptrader] 21/6/2020 12:17

Several respected posts on twitter last week promoting covid-19 pharma plays, IDH not a single mention.
The most popular ones: AVCT, NCYT, TLS, ODX, GDR, HEMO, BRH .... what do they all have in common ?! yep, a fundraise. ( where the shares need shifting).

Unless you need a fundraise, you don't get the pumping. Cynical or what ?!

[hedgehog 100] 20/6/2020 20:30

Thanks for that 2toptrader.

The negative impact of the lockdown on laboratory testing is very temporary, and we're already emerging from it. It will soon be forgotten.

Whereas the massive need for COVID-19 testing will be ongoing, and this is what investors here will now focus on.

And in this respect, IDH are planning to launch a range of COVID-19 antibody tests by the end of this month (i.e. the first quarter of their financial year), which could hardly be much more near-term :

17/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Final Results
" ... Jaap Stuut, CEO of IDS, commented:
"During FY2020 we delivered a second consecutive year of like for like revenue growth, with revenue increasing by 2% to GBP39.3m. We also increased the number of analysers sold or placed to 150, compared to 127 in FY2020. Adjusted EBITDA improved to GBP6.1m from GBP4.8m in the prior year. Our results in Q1 of FY2021 will be significantly impacted by reduced laboratory testing volumes, however once the pandemic subsides, we believe we are in a strong position to continue our revenue growth. Additionally, we have an opportunity to commercialise our range of automated and manual SARS-CoV-2 antibody testing kits, which we plan to launch during June 2020. ...
In the short term we will also focus on commercialising opportunities arising from Increased levels of SARS-CoV2 antibody testing using a range of automated and manual test kits which we expect to launch during Q1 FY2021. ..."